SCHEMBL76511

SCHEMBL76511

C#CCOC(C(=O)OCCOC(=O)C(OCC#C)c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.37
SLC22A12 Q96S37 1/20 0.37
NPC1 O15118 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
PPARA Q07869 1/20 0.35
GPX4 P36969 1/20 0.35
GABBR2 O75899 3/20 0.33
GABBR1 Q9UBS5 3/20 0.33
LMNA P02545 2/20 0.33
CYP2C9 P11712 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
TSHR P16473 2/20 0.33
BRD4 O60885 1/20 0.33
CYP3A4 P08684 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
NFKB1 P19838 1/20 0.33
DRD3 P35462 1/20 0.33
BLM P54132 1/20 0.33
HDAC4 P56524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL85757 0.93 PPARG (0.35) PPARGSLC22A12NPC1MAOAMAOB
SCHEMBL77404 0.92 NPC1 (0.40) PPARGNPC1MAOAMAOBPPARA
SCHEMBL76267 0.87 L3MBTL1 (0.44) L3MBTL1BRD4HDAC4HDAC7HDAC5
SCHEMBL5917972 0.84 PPARG (0.36) PPARGNPC1MAOAMAOBPPARA
SCHEMBL75610 0.84 PPARG (0.46) PPARGMAOAMAOBPPARAGPX4
Hydrochloric Acid SCHEMBL5918049 0.83 PPARG (0.44) PPARGMAOAMAOBPPARAGPX4
SCHEMBL76084 0.73 LMNA (0.38) GPX4LMNACYP2C9L3MBTL1TSHR
SCHEMBL77607 0.72 TSHR (0.39) NPC1MAOAMAOBLMNACYP2C9
SCHEMBL5917965 0.71 IDO1 (0.32) GPX4GABBR2GABBR1LMNACYP2C9
SCHEMBL14558224 0.70 ADRB2 (0.41) LMNATSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919857-B1 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2016-03-09 EP disclosed
EP-1919857-B1 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2016-03-09 EP disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
EP-1919857-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF Syngeta Participations AG (CH) 2008-05-14 EP disclosed
WO-2007020381-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2007-02-22 WO disclosed
WO-2007020381-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof OPRM1, OPRD1, ADRA1D PPARG 4173/4885SLC22A12 4212/4885NPC1 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.